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   Malignant tumors remain one of the leading causes of 
death in the world among chronic non-infectious diseases, 
with over 7.6 million deaths registered every year (13% of 
all deaths). The number of deaths from cancer is predicted 
to reach 11 million per year by 2030 [1, 2]. The high prev-
alence of cancer in Ukraine (348 per 100 thousand popu-
lation) determines its social and economic signifi cance 
and makes cancer a prioritized area for the allocation of 
healthcare resources [3]. Survival of cancer patients one 
year after diagnosis is 65.9% in Ukraine, which is not sig-
nifi cantly different from the European average (67.3%) 
but considerably lower than in such countries as Island, 
Finland, Switzerland and Sweden [4]. 
Malignant tumors of lymphoid and hematopoietic tis-
sues (ICD-10 C81-C96) are fairly common among adults 
in economically developed European countries [2,4]. 
According to the 11th issue of the National Cancer Reg-
istry (2010), morbidity and mortality due to lymphopro-
liferative disorders are also rather high in Ukraine (Fig. 
1). For instance, mortality within one year of diagnosis 
is 39.3% for leukemia, 36.1% for multiple myeloma 
(MM), 36.5% for non-Hodgkin’s lymphomas (NHL), and 
12% for Hodgkin’s lymphoma (HL). Five-year survival 
rate of Ukrainian patients with leukemia is 26.3%, NHL 
28.5%, and HL 48.7%. The social signifi cance of lympho-
mas and leukemias is further amplifi ed due to their high 
prevalence among people of working age: HL, leukemias 
and NHL are among the fi ve top malignancies affecting 
men between 18 and 29 years of age (16%, 10.5% and 
6.5%, respectively). HL is the most common type of can-
cer among women of this age group (15.1%) [3]. Even 
though mortality due to these conditions is high, it is pos-
sible to achieve a cure or improve the patient’s quality 
of life if the disease is diagnosed at an early stage and 
the patient is given timely treatment. In order to improve 
the supply of drugs for pharmacotherapy and promote the 
spread of evidence-based therapy in clinical practice, it is 
important to analyze the pharmaceutical market as well as 
the currently used and recommended methods of treating 
malignant tumors of lymphoid and hematopoietic tissues.
Even though tumors of lymphoid and hematopoietic 
tissues are not among the fi ve most common cancers in 
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Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are two of the most widespread lymphoproliferative disorders among the adult popu-
lation of Ukraine and other Central and Western European countries. Considering that pharmaceutical treatment accounts for the major part of medical 
expenses in the management of these conditions, the aim of this study was to assess the costs of pharmacotherapy of CLL and MM. The analysis was 
performed retrospectively using the results of our own pilot study, in which we examined medical histories of the patients treated at a specialized medical 
center in Kiev. The average annual cost of pharmacotherapy of all Ukrainian patients was 340 750 162 RUB for CLL and 89 184 759 RUB for MM. We 
found a negative correlation between the patient’s age and the cost of pharmacotherapy. 
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Region of Russia and CIS
Fig. 1. Lymphoproliferative disor-
ders in Ukraine: morbidity and mor-
tality.
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Ukraine, potentially they could have a major economic 
impact compared to other malignancies. A systematic re-
view of studies that included patients with different types 
of cancer demonstrated that non-localized tumors, such as 
lymphoproliferative disorders, are associated with higher 
treatment costs [5]. Considering that CLL and MM are 
among the most common lymphoproliferative disorders 
[3], the objective of this study was to perform a pilot 
analysis of the cost of treating these cancers in Ukraine. 
According to the available publications, pharmacotherapy 
is the single largest component of total medical costs as-
sociated with the treatment of patients with lymphoprolif-
erative disorders [6-10]. Because of this, only the costs of 
pharmacotherapy were included in the analysis.
MATERIALS AND METHODS
Our pilot evaluation of the cost of treating CLL and 
MM was performed using case report forms of the Na-
tional Institute of Hematology (Kiev). The electronic da-
tabase of this organization (Access software) contained 
data taken from medical histories of patients with CLL 
and MM, which we used for our retrospective analysis. 
The data were transferred from the case report forms to 
the database by a qualifi ed member of the hospital staff 
(an assistant). Newly diagnosed patients and those who 
relapsed and were hospitalized at least once between 2006 
and 2010 for CLL or MM were included in the analysis. 
Overall, the sample of MM patients consisted of 98 indi-
viduals aged between 29 and 81 (mean age 62.5), 35.6% 
of whom were males. The sample of CLL patients consist-
ed of 113 individuals aged between 39 and 85 (mean age 
61.3), with 61.9% males. The following characteristics 
were derived from the medical histories: age and gender, 
the stage of cancer progression, treatment administered, 
and disease duration.
We analyzed the cost of pharmacotherapy for the main 
diagnosis and comorbidities, such as anemia and bone 
diseases accounting for the possibility that the medica-
tions may be acquired by the patients themselves as well 
as by the state. To estimate the costs, we analyzed the 
structure of state purchases in 2010 based on eight Orders 
of the Ministry of Health of Ukraine (No. 360, 365, 526, 
608, 686, 687, 980, 987). The spending on pharmaceuti-
cal drugs purchased under the governmental scheme in 
2010 was assumed to be equal to these tariffs. The cost 
of medications purchased by the patients was estimated 
based on the prices quoted by distributors, assuming a 
35% pharmacy surcharge. The currency was converted 
according to the rate of the Central Bank of Russia on 
24.03.12 (1 hryvnia = 3.66 rubles). The statistical analysis 
of the correlation between the costs and the patient’s age 
at diagnosis was performed in SPSS 12.0.
RESULTS
The analysis of medical histories revealed that CLL 
patients were usually prescribed cyclophosphamide, fl u-
darabine, and vincristine. Patients diagnosed with MM 
usually received a combination of melphalan, prednisolo-
ne or dexamethasone and/or talidomide. Among the drugs 
prescribed to these patients, corticosteroids had the lowest 
cost of the median daily dose, while bortezomib (MM) 
and rituximab (CLL) had the highest (Table 1). 
The average annual cost of pharmacotherapy of 
one MM patient was 20 114 RUB (range: from o to 
Table 1. The cost of medications commonly administered to patients with MM and CLL
Drug Cost of median daily dose, RUB Range, RUB
Alemtuzumab 1571.81 -
Bortezomib 66 049.57 -
Vincristine 130.79 130.79 – 261.19
Dexamethasone 4.66 1.55 – 6.98
Zoledronic acid 11 069.39 -
Ibandronic acid 9677.66 -
Interferon alpha-2b 7606.37 -
Clodronic acid 44.24 -
Lomustine 10.48 5.05 – 15.52
Melphalan 123.03 123.03 – 368.67
Methylprednisolone 0.78 0.39 – 1.55
Pamidronic acid 3620.59 -
Prednisolone 0.39 0.16 – 1.64
Rituximab 55 149.01 36 675.45 – 80 414.32
Talidomide 11.25 5.43 – 22.13
Fludarabine 21 772.41 18 745.23 – 21 772.41
Chlorambucil 1.86 1.96 – 51.32
Cyclophosphamide 31.44 15.52 – 62.10
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62 527 RUB). Considering the prevalence of MM in 
Ukraine (4 434 cases), the total cost of pharmacotherapy 
of MM in Ukraine may be estimated at 89 184 759 RUB/
year. The treatment of bone diseases associated with 
MM constitutes a considerable part of total expenses. 
On average, this treatment costs 2746 RUB per year 
per patient (from 0 to 5208 RUB). The most economi-
cally signifi cant type of primary treatment is bortezomib 
therapy. If we exclude patients receiving bortezomib 
from the analysis, the total cost of pharmacotherapy 
drops to 4179 RUB (from 0 to 6819 RUB). Of this sum, 
2487 RUB was spent on the treatment of bone diseases 
with bisphosphonates (ibandronic, pamidronic, clodron-
ic, and zoledronic acids) (Fig. 2).
The average annual cost of treating one CLL patient 
was 39 892 RUB (from 0 to 771 272 RUB). Consider-
ing the prevalence of CLL in Ukraine (8542 cases), the 
total annual cost of CLL pharmacotherapy amounts to 
340 750 162 RUB. Prescription of therapeutic combina-
tions including fl udarabine and rituximab had the greatest 
impact on the cost of CLL treatment. The average cost of 
a course of monotherapy with injectable fl udarabine (50 
mL for 3 days) is 21 080 RUB. The cost of one course of 
therapy with the median dose of rituximab (400 mg/day) 
is 36 505 RUB.
Statistical analysis of the collected data revealed 
that there was a negative correlation between the age of 
the patient at the time of diagnosis and the cost of treat-
ment, both for CLL (t = -2.108, p < 0.05) and for MM 
(t = -2.118, p < 0.05). This contradicts the results of 
similar studies performed in other countries, in which 
the cost of treating elderly patients with these condi-
tions was higher [6,7,10,11]. The limitations of the reg-
istry that we used provide one possible explanation of 
this result, since it did not allow us to take into account 
fully all the additional costs associated with treating 
the complications of the main disease and comorbidi-
ties. Among such medical conditions that are common-
ly found in patients suffering from lymphoproliferative 
disorders are infectious diseases, renal failure, and ane-
mia. It is likely that the registry did not fully document 
the therapy administered for these conditions. Another 
possible reason why the treatment of elderly patients 
with lymphoproliferative disorders did not cost more is 
the low income of this age group, limiting their ability 
to pay for the treatment and encouraging the physicians 
to prescribe cheaper drugs.
From 01.04.2012 the lowest living cost in Ukraine 
for incapacitated people is set at 3067 RUB. The treat-
ment of CLL and MM is a considerable economic bur-
den for patients, especially for exposed groups such as 
impecunious elderly patients. This highlights the need 
to provide elderly patients with additional fi nancial sup-
port, since for them malignant tumors are associated 
with greater fi nancial and emotional diffi culties than for 
younger people [12].
LIMITATIONS OF THIS STUDY AND 
RECOMMENDATIONS
Retrospective analysis of medical histories in a single 
medical center only amounts to a pilot study that may of-
fer an approximate estimate of the cost of treating lym-
phoproliferative disorders in Ukraine. This analysis does 
not allow us to assess indirect costs of treatment. In order 
to generalize from the results obtained in the study sample 
to the general population of patients, we have to compare 
our results with the data from other medical centers, thus 
arriving at a representative sample of patients.
CONCLUSIONS 
1. Our pilot analysis of the costs of pharmacotherapy 
demonstrated that the average annual cost of medications 
was 39 892 RUB for CLL patients and 20 114 RUB for 
MM patients. Even though less than 10% of all patients 
with lymphoproliferative disorders were receiving the 
most expensive drugs, such as rituximab (CLL therapy) 
and bortezomib (MM therapy), the use of these drugs had 
a major impact on the total spending. The expediency of 
Fig. 2. The average annual cost 
of pharmacotherapy of 1 patient 
with MM.
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their use in clinical practice needs to be justifi ed with the 
help of pharmacoeconomic analysis.
2. According to the results of this study, elderly pa-
tients are likely to be given less expensive treatment, 
which may be related to the high cost of therapy if these 
conditions are treated in accordance with the protocols 
developed upon the principles of evidence-based medi-
cine. This hypothesis needs to be tested by means of a 
more detailed analysis.
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